If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma showcases PureHale and QuickStartTM Injectables product launches

    Quick Contact
    • Aptar Pharma
    Aptar Pharma showcases PureHale and QuickStartTM Injectables product launches
    Europe, France, Switzerland, France, Eye Care, Health, Pharmaceuticals, Drug Delivery Devices, Active, Smart Packaging, Shows, Associations, Media, Packaging Trade Shows, Events, Pharmapack, Packaging Awards

    Aptar Pharma, a leading drug delivery systems provider, will once again be a major exhibitor at Pharmapack 2019, which will take place February 6-8 at Paris Expo, Porte de Versailles, in Paris, France.

    Located at booth B42, Hall 7.2, Aptar Pharma will present their diverse portfolio of drug delivery systems, components and active packaging solutions, including their latest innovations across nasal, pulmonary, eye care, injectables and dermal drug delivery routes:

    • PureHale - their recently launched, portable and ready-to-use device designed to deliver natural care to upper airways
    • Their expanded range of connected drug delivery devices designed to help increase dose adherence and improve patient health outcomes
    • Aptar Pharma Services, a portfolio of stage-specific development packages to help customers accelerate their development journey from molecule to market
    • Active packaging solutions from Aptar CSP Technologies, now part of the Aptar family. Aptar CSP Technologies offers a variety of innovative active packaging solutions to help optimize your drug product’s packaging environment

    Considered Europe's dedicated pharmaceutical packaging and drug delivery event, Pharmapack provides invaluable insight into and recognition of the latest trends, developments and regulatory changes impacting the industry, as well as a wide variety of learning opportunities.

    As part of the Innovation Gallery at Pharmapack this year, Aptar Pharma will showcase two of their newest product launches, PureHale and QuickStartTM Injectables – their Ready-to- Use drug development support packages designed to accelerate time-to-market for research and development labs. Both innovations are contenders for the Pharmapack 2019 Awards, which will be announced during the show.

    Once again, three of Aptar Pharma’s experts will share their specialist knowledge during Pharmapack’s Learning Lab sessions on Wednesday, February 6:

    • Drug Repurposing – Broadening Patient Accessibility via a Change in Drug Delivery System (13:50 – 14:20). Dr. Gerallt Williams, Director - Scientific Affairs at Aptar Pharma, will discuss the advantages and challenges of drug repurposing, some successful transitions and the regulatory factors which need to be considered
    • Building a Successful Eco-System for Digital Medicines (14:30–15:00). Sai Shankar, Director Business Development – Connected Devices, will discuss how to build a successful digital medicines eco-system, its impact on patient health outcomes and the overall healthcare system, as well as the stakeholder’s perspective
    • Debunking the Leachable Myths of Gamma Sterilization: A Migration Study of Steam versus Gamma (15:10–15:40). Dr. Julie D. Suman, President and Founder of Next Breath, an Aptar Pharma business, will present the results of a migration study commissioned by Aptar Pharma to assess the impact of both steam and gamma sterilization on leachable profiles.

    With over 400 exhibitors and more than 5,000 Pharma & drug delivery professionals expected to attend Pharmapack this year, Aptar Pharma welcomes the opportunity to meet with their customers and partners from around the world at this key industry event.

    Visit Aptar Pharma at Booth B42, Hall 7.2, where their team of experts will be on hand to demonstrate their technologies and discuss ways they can partner with customers to ensure their drug delivery challenges are met.

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 18 Dec 2018
    • Hits 1104
    Sun-Rain
    APG
    Epopack